NRG Oncology/RTOG 9813 综合分子分析:间变性星形细胞瘤放疗联合替莫唑胺对比放疗联合BCNU/CCNU的3期研究
该3期研究对NRG Oncology/RTOG 9813中79例间变性星形细胞瘤患者进行分子分析,应用2021 WHO标准将26/79(33%)患者重新分类为IDH突变型4级星形细胞瘤或胶质母细胞瘤。新分子分级下3级患者生存优于4级患者;IDH1/2突变、MGMT启动子甲基化和ATRX突变各自与较长生存相关,而TERT启动子突变、EGFR扩增和7号染色体获得/10号染色体丢失与较短生存相关。MGMT甲基化患者接受RT+TMZ或RT+BCNU/CCNU以及MGMT未甲基化患者接受RT+TMZ的生存结局相似,IDH突变患者似乎对加用TMZ反应良好。
要点
- 2021 WHO标准将26/79(33%)间变性星形细胞瘤重新分类为4级。
- IDH1/2突变、MGMT甲基化和ATRX突变各自与较长生存相关。
- TERT启动子突变、EGFR扩增和Chr+7/-10与较短生存相关。
核心结论
- 本研究证明按2021 WHO标准分类患者的重要性,多数IDH野生型间变性星形细胞瘤(3级)被重新分类为胶质母细胞瘤(4级)。
- 分析揭示TMZ在某些分子亚组中的疗效,RT加用TMZ似乎使患者获益,无论MGMT甲基化状态如何。
研究设计与样本
- NRG Oncology/RTOG 9813是一项3期研究,比较放疗联合替莫唑胺与放疗联合BCNU/CCNU在间变性星形细胞瘤中的疗效。
- 突变状态通过免疫组化和/或二代测序确定,拷贝数改变和MGMT甲基化通过Affymetrix Oncoscan和/或Illumina 450K芯片确定。
- 无进展生存和总生存采用Kaplan-Meier法估计,log-rank检验比较,多变量分析使用Cox比例风险模型。
主要发现
- 应用2021 WHO标准将26/79(33%)患者重新分类为IDH突变型4级星形细胞瘤或胶质母细胞瘤。
- 按新分子分级,3级患者生存结局长于4级患者。
- IDH1/2突变、MGMT启动子甲基化和ATRX突变各自与较长生存相关。
- TERT启动子突变、EGFR扩增和7号染色体获得/10号染色体丢失(Chr+7/-10)与较短生存相关。
- MGMT甲基化患者接受RT+TMZ或RT+BCNU/CCNU以及MGMT未甲基化患者接受RT+TMZ的生存结局相似;IDH突变患者似乎对加用TMZ反应良好。
关键数值与推荐
- 2021 WHO标准重新分类26/79(33%)患者为4级。
- IDH1/2突变、MGMT启动子甲基化、ATRX突变各自与较长生存相关。
- TERT启动子突变、EGFR扩增、Chr+7/-10与较短生存相关。
临床怎么用
- 按2021 WHO标准对间变性星形细胞瘤进行分子分类以预测临床结局。
- RT加用TMZ似乎使患者获益,无论MGMT甲基化状态如何。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is a need to better understand the molecular features that characterize grade 3 astrocytomas and their significance in predicting clinical outcomes. The aim of this study was to determine the significance of the 2021 World Health Organization (WHO)-defined molecular subgroups, along with MGMT promoter methylation, and other alterations in NRG Oncology/RTOG 9813. METHODS AND MATERIALS: Mutation status was determined by immunohistochemistry and/or next-generation sequencing. Copy number alterations and MGMT methylation were determined by Affymetrix Oncoscan and/or Illumina 450K arrays. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and tested using the log-rank test. Multivariable analyses used Cox proportional hazards models. RESULTS: Application of the 2021 WHO-defined criteria resulted in the reclassification of 26/79 (33%) patients to grade 4 astrocytoma, IDH-mutant or glioblastoma. When looking at newly assigned molecular grade, grade 3 patients experienced longer survival outcomes compared to grade 4 patients. As individual biomarkers, IDH1/2 mutations, MGMT promoter methylation, and ATRX mutations were each associated with longer survival, whereas TERT promoter mutations, EGFR amplification, and gain of chromosome 7/loss of 10 (Chr+7/-10) were associated with shorter survival. Similar survival outcomes were observed for MGMT methylated patients treated with radiation therapy (RT) and temozolomide (TMZ) or RT and BCNU/CCNU, and MGMT unmethylated patients treated with RT and TMZ. Additionally, IDH-mutant patients seemed to respond well to the addition of TMZ. CONCLUSIONS: This study demonstrated the importance of classifying patients according to the 2021 WHO-defined criteria. The majority of IDH-wildtype anaplastic astrocytomas (grade 3) were reclassified as glioblastoma (grade 4). These analyses also shed light on the efficacy of TMZ in certain molecular subgroups, where the addition of TMZ to RT appeared to benefit patients regardless of MGMT methylation status.
引用
- Fleming JL, Pugh SL, Chang SM, et al. Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2025. PMID: 40164352. doi:10.1016/j.ijrobp.2025.03.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。